Sernova Biotherapeutics Inc (LSX:A411DW) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Convertible notes and common stock purchase warrants of Seraxis Closed: US$11.2M raised Buyers: Dr. Steven Sangha / Arlo Investments; Jonathan Rigby; Will Rust Insiders: Insiders participated, including Dr. Steven Sangha / Arlo Investments, Sernova management and Seraxis management Use of proceeds: cGMP manufacturing of SR-02 islet cells and enrollment of T1D patients for the Phase 1/2 clinical trial | Oct 5, 2026 | |
| Unsecured convertible debentures Closed: C$1.5M raised · C$0.15 · Warrants at C$0.25 for 36 months Insiders: Financing made with an insider; insiders participated, treated as related party transactions | Apr 23, 2026 | US$1.1M |
| Private placement of units Closed: C$4M raised Insiders: Unit financing made with an insider; insiders participated, treated as related party transactions Use of proceeds: To retire outstanding loan obligations | Apr 23, 2026 | US$2.92M |
| Private placement of units Update: C$4M · C$0.15 a unit · 1 warrant at C$0.2 for 36 months Insiders: Shareholders approved the issuance of the units to an insider of the Company Use of proceeds: Retire the existing $4.0 million secured term loan maturing April 16, 2026 | Apr 9, 2026 | US$2.93M |
| Private placement of units Announced: C$1.6M · C$0.15 a unit · 1 warrant at C$0.25 for 36 months | Mar 4, 2026 | US$1.17M |
| Private placement of units Tranche closed: C$874,600 raised · C$0.16 a unit · 1 warrant at C$0.4 for 36 months Use of proceeds: General operating capital and launch of final Cohort C in the Phase 1/2 trial of its Cell Pouch Bio-hybrid Organ for type 1 diabetes | Nov 13, 2025 | US$623,912 |
| Unsecured convertible debenture Closed: C$1M raised · Warrants at C$0.2 Buyers: Dr. Steven Sangha (CAD$1,000,000 unsecured convertible debenture and 5,000,000 warrants) Insiders: The debenture and warrants were issued to Dr. Steven Sangha, a shareholder and board member; a related party transaction under MI 61-101 Use of proceeds: Working capital | Mar 5, 2025 | US$695,894 |